Home Latest Articles
Latest Articles
  • Chunxia REN, Xiaochun FU, Tingting WU, Rong ZHOU, Zicheng YU
    World Clinical Drug. 2024, 45(2): 213-216.

    Patients with advanced chronic kidney disease (CKD) have a higher risk of venous thromboembolism and atrial fibrillation and need to receive anticoagulant therapy. At the same time, patients with advanced CKD also have an increased risk of bleeding, which complicates antithrombotic therapy. Therefore, special attention should be paid to the rational selection and use of anticoagulant drugs in advanced CKD patients. The application of novel oral anticoagulant in advanced CKD patients is noteworthy because of the rapid effect, short half-life and no need for laboratory indicator monitoring.

  • Bo SHU, Yanfei JIANG, Guanghua CHEN, Tingting XING
    World Clinical Drug. 2024, 45(2): 217-222.
    Objective

    To establish the evaluation rules of drug utilization for Shenmai injection, and to explore the application of analytic hierarchy process model (AHM) weighting combined with technique for order preference by similarity to solution (TOPSIS) method in the evaluation of drug utilization rationality of Shenmai injection.

    Methods

    Based on the instructions of Shenmai injection and relevant guidelines, the evaluation criteria for drug utilization of Shenmai injection were established. The rationality of the use of Shenmai injection in 220 patients in the Affiliated Hospital of North Sichuan Medical College (hereinafter referred to as 'our hospital') from January 2022 to December 2022 was retrospectively evaluated by AHM combining with TOPSIS.

    Results

    There were 6 cases (2.73%) with reasonable medication (Ci≥0.8), 185 cases (84.09%) with basically reasonable medication (0.6≤Ci<0.8), and 35 cases (15.91%) with unreasonable medication (Ci<0.6) among the 220 medical records. Disease diagnosis, solvent selection, drug concentration, special population, ADR monitoring and treatment, precautions and course records were the main factors leading to irrational use of Shenmai injection.

    Conclusion

    The evaluation results obtained by AHM weighting combined with TOPSIS method are quantitative, scientific and credible, and can be used to evaluate the rationality of drug use of Shenmai injection.

  • Anni WANG, Yifan LI, Xin FENG
    World Clinical Drug. 2024, 45(2): 223-227.
    Objective

    To explore the influence of clinical pharmacists on the level of knowledge, attitude, practice (KAP) in patients with threatened abortion.

    Methods

    Patients with threatened abortion in the obstetrics clinic of our hospital from March 2020 to August 2020 were selected as the baseline group (386 cases). Patients with threatened abortion in the obstetrics clinic of our hospital from March 2021 to August 2021 were selected as the popular science intervention group (321 cases). The intervention group received medication education and guidance from clinical pharmacists on the popularization of threatened abortion and related drug popularization intervention manuals. The KAP level of the two groups was evaluated by the questionnaire on knowledge, attitude and practice of safe medication behavior of pregnant women. The score difference between the two groups was compared, and the factor analysis was used to explore the key issues affecting the KAP level.

    Results

    The total questionnaire scores of baseline group and popular science intervention group were (87.75±8.65) pionts and (101.29±12.69) pionts, respectively. In the baseline group, the average score of knowledge was (24.63±4.42) pionts, the average score of attitude was (29.68±4.65) pionts, and the average score of behavior was (33.44±6.78) pionts, which was lower than the (27.65±5.44), (34.15±6.22) and (39.49±7.00) pionts of the popular science intervention group.

    Conclusion

    The awareness of drugs in the popular science intervention group was significantly higher than that in the baseline group, suggesting that the comprehensive management mode of pharmaceutical intervention by clinical pharmacists could improve the level of KAP in patients with threatened abortion.

  • Fengyi LYU, Guangtao XIA
    World Clinical Drug. 2024, 45(1): 1-4.

    Micro RNA (miR) is a class of endogenous non-coding small molecule RNA with a length of 20 -23 nucleotides, which is an important regulator of immune response. MiR-326 is involved in various pathophysiological processes in vivo, regulating various cell homeostasis and differentiation, including immune cells, and is closely related to multiple autoimmune disease (AID), which is expected to become a new therapeutic target. This article reviewed the relationship between miR-326 and AID and immune cells and the research progress, aiming to provide some reference for the research of new drugs.

  • Lei QIN, Fengyi LYU, Xiaoqing WANG
    World Clinical Drug. 2024, 45(1): 5-10.

    B cell and humoral immunity play an important role in the occurrence and development of autoimmune disease (AID). B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are necessary for the maintenance of B cell bank and humoral immunity. Telitacicept is a fusion protein of the Fc segment of APRIL and BAFF receptor transmembrane protein activator and immunoglobulin G, which can be used to treat AID. This article discussed the mechanism of action of telitacicept and its progress in the treatment of AID, including systemic lupus erythematosus, autoimmune nephropathy, neuromyelitis optica spectrum disorder and primary Sjogren's syndrome, in order to provide some reference for clinical use.

  • Dan LI, Na LI, Ying LIANG, Xunting LI, Sujuan CAO
    World Clinical Drug. 2024, 45(1): 11-17.
    Objective

    To investigate the effects of plasma exosomal micro RNA (miR)-21 on the growth and metastasis of diffuse large B-cell lymphoma (DLBCL) cells and its mechanism.

    Methods

    Extraction and identification of plasma exosomes from DLBCL patients. U2932 cells were divided into miR-21 mimic negative control (NC) group, miR-21 group, miR-21+phosphatase and tensin homolog deleted on chromosome ten (PTEN) group, phosphate buffer solution (PBS) group, DLBCL exosome group, DLBCL exosome+miR-21 inhibitor group (A group), DLBCL exosome+PTEN group (B group). Real time fluorescent quantitative polymerase chain reaction was used to detect miR-21 expression in U2932 cells. Dual luciferase was used to verify the targeting relationship between miR-21 and PTEN. The proliferation, migration and invasion ability of U2932 cells were detected by cell counting kit-8 and Transwell assay.

    Results

    The exosomes of DLBCL patients had a bilayer membranes with a "saucer-like" shape, with a particle size of 30~100 nm. The marker proteins tumor susceptibility gene 101, cluster of differentiation 9 and heat shock protein 70 were expressed on the surface. Dual luciferase reporter gene assay showed that PTEN was the target gene of miR-21. Compared with the miR-NC group, the proliferation, migration and invasion abilities of the U2932 cells in the miR-21 group were significantly increased (P<0.05). Compared with miR-21 group, the proliferation, migration and invasion ability of U2932 cells in miR-21+PTEN group were significantly decreased (P<0.05). Compared with PBS group, the expression of miR-21 in plasma exosome U2932 cells of DLBCL patients was significantly increased, and cell proliferation, migration and invasion were significantly enhanced (P<0.05). The proliferation, migration and invasion ability of U2932 cells in A and B groups were significantly lower than those in the plasma exosome group of DLBCL patients (P<0.05).

    Conclusion

    The plasma exosome miR-21 promotes the proliferation, migration and invasion of U2932 cells by inhibiting PTEN.

  • Jing ZHAO, Jian ZHANG, Aimin HU, Yi TAO, Ling YAN
    World Clinical Drug. 2024, 45(1): 18-25.
    Objective

    To investigate the protective effect of buyang huanwu decoction on diabetic peripheral neuropathy (DPN) through phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) autophagy pathway.

    Methods

    Forty-eight Wistar rats were grouped into control group (gavage+intravenous sterile saline solution of equal volume), DPN model group (gavage+intravenous sterile saline solution of equal volume), traditional Chinese medicine treatment group (gavage 2 g/kg buyang huanwu decoction) and PI3K inhibitor group (gavage 2 g/kg buyang huanwu decoction+intravenous 1.5 mg/kg PI3K inhibitor LY2940002). Except for the control group, DPN rats in the other three groups were given the corresponding drug treatment. The conduction index and the ultrastructure of the sciatic nerve were observed. Serum factor expression levels and neuronal autophagy and apoptosis was analyzed. Expression levels of relevant proteins were examined.

    Results

    Compared with the control group, the sciatic nerve myelin axons were severely lost in DPN model group, the myelin sheath was destroyed and curled, the organelles were reduced, the speed and amplitude of the sciatic nerve conduction action sites were decreased, the levels of autophagy and apoptosis were increased, and the levels of PI3K/Akt pathway was inhibited, and the differences were statistically significant (P<0.01). The above indexes were improved in the Chinese medicine treatment group, including ultrastructural changes, autophagy, apoptosis and PI3K/Akt pathway-related protein levels (P<0.01). However, PI3K inhibitor partially reversed the protective effect of buyang huanwu decoction on DPN rat model (P<0.01).

    Conclusion

    Buyang huanwu decoction may inhibit apoptosis and autophagy by activating the PI3K/Akt pathway, thereby exerting a protective effect on DPN rats.

  • Bing YU, Meng ZHANG, Fei GUO, Huiting LI
    World Clinical Drug. 2024, 45(1): 26-31.
    Objective

    To evaluate the efficacy and safety of nabuliumab combined with ipilimumab in the first-line treatment of locally advanced lung adenocarcinoma.

    Methods

    Ninety-two patients with locally advanced lung adenocarcinoma were randomly divided into control group and combined group by random number table method, 46 cases in each group. The control group received pemetrexed combined with cisplatin, and the combined group received nabuliumab combined with ipilimumab. Disease control rate (DCR), objective response rate (ORR), safety, tumor downstaging rate, major pathological response (MPR), pathological complete response (pCR) rate and tumor markers were compared between the two groups.

    Results

    The rates of ORR, DCR, tumor downstaging in the combined group were higher than those in the control group (P<0.05), and the incidence of adverse reaction in grade Ⅲ and above was lower than that in the control group (P<0.05). After 2 months of treatment, serum carcino-embryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (Cyfra21-1) and neurone-specific enolase (NSE) levels in 2 groups were decreased compared with those before treatment (P<0.05), and serum CEA, Cyfra21-1 and NSE levels in combined group were significantly lower than those in control group (P<0.05).

    Conclusion

    Nabuliumab combined with ipilimumab in the first-line treatment of locally advanced lung adenocarcinoma can increase ORR, DCR, tumor descending stage rate, and the adverse reactions are controllable.

  • Ruihong SONG, Liumei PU, Liwen LU
    World Clinical Drug. 2024, 45(1): 32-37.
    Objective

    To explore the clinical effect of different inhaled drugs on patients with moderate or severe chronic obstructive pulmonary disease (COPD) in stable phase.

    Methods

    180 patients with moderate or severe stable COPD treated in our hospital from July 2020 to July 2022 were randomly divided into three groups: A group, B group and C group, and 60 cases in each group. The patients in A group were given tiotropium bromide, the patients in B group were given salmeterol/ticasone, and the patients in C group were treated with umeclidinium bromide/vilanterol trifenatate. Pulmonary function index, blood gas index, level of inflammatory factors and adverse events during intervention were compared before and after treatment among the three groups.

    Results

    After intervention, the clinical effective rate of A, B and C group increased successively, and the differences were statistically significant (P<0.05). The levels of forced expiratory volume in one second (FEV1), FEV1% pred and FEV1/forced vital capacity (FVC) in group C were significantly higher than those in A and B group (P<0.05), but there was no significant difference in the level of peak expiratory flow (PEF) among the three groups (P>0.05). The levels of PaO2 and SaO2 in group C were significantly higher than those in A and B group (P<0.05), while the level of PaCO2 in C group was significantly lower than that in A and B group (P<0.05). The levels of IL-6, IL-8 and TNF-α in C group were similar to those in B group (P>0.05) and significantly lower than those in A group (P<0.05). During the intervention period, the number of acute attacks in C group was significantly lower than that in A and B group (P<0.05), but there was no significant difference in adverse events among the three groups (P>0.05).

    Conclusion

    Umeclidinium bromide/vilanterol trifenatate can effectively improve pulmonary function and blood gas indexes, reduce inflammatory reaction, reduce the risk of acute attack in patients with moderate or severe stable COPD, with good safety.

  • Zhuxin MAO, Lingxiang ZHUANG, Shitong XIE, Jing WU
    World Clinical Drug. 2024, 45(1): 38-44.
    Objective

    To explore the treatment preferences of oral antidiabetic medications in Chinese type 2 diabetes patients.

    Methods

    Patients with type 2 diabetes were recruited and interviewed in three hospitals of different levels in Beijing. Semi-structured interviews were conducted to collect the factors that patients would consider when choosing oral antidiabetic medications. The interviews were recorded and transcribed into texts. Techniques of grounded theory were used to code important information from the texts. The extracted codes were summarized, classified and generated themes.

    Results

    A total of 27 patients were included in the study. Based on qualitative data analysis, five themes were summarized, namely, attention to efficacy, avoidance of medication risks, consideration of medication burden, consideration of medication costs, and the favor of reliable medication.

    Conclusions

    Patients with type 2 diabetes consider multiple aspects when evaluating and choosing oral antidiabetic medications. Healthcare services providers should focus on the medication preferences of people with type 2 diabetes to develop patient-centered treatment plans to achieve optimal adherence and clinical outcomes, and ultimately improve their health and well-being.

News